SCHEMBL138570

SCHEMBL138570

CC(C)(C)OC(=O)N1CCC(=O)CC1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
ESR2 Q92731 1/20 0.36
CTSK P43235 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
NR1H2 P55055 1/20 0.35
KDM1A O60341 1/20 0.35
HPGD P15428 1/20 0.34
UCHL1 P09936 1/20 0.34
BUB1 O43683 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28974037 0.90 LMNA (0.41) USP2SMN1; SMN2DDB1CRBNCHRM2
SCHEMBL513188 0.87 USP2 (0.43) USP2SMN1; SMN2DDB1CRBNCHRM2
SCHEMBL3738925 0.81 CHRM2 (0.40) USP2SMN1; SMN2DDB1CRBNCHRM2
SCHEMBL10199690 0.81
Tetrahydrofuran SCHEMBL28264888 0.80 USP2 (0.50) USP2SMN1; SMN2DDB1CRBNCHRM2
SCHEMBL6519434 0.80 CHRNA7 (0.36) USP2SMN1; SMN2DDB1CRBNCHRM2
SCHEMBL205421 0.80 LMNA (0.48) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL7495565 0.79 LMNA (0.47) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL42476 0.79 SMN1; SMN2 (0.48) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL31551856 0.77 SMN1; SMN2 (0.50) USP2SMN1; SMN2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108604-B Process for preparing tricyclic lactam compounds 豪夫迈·罗氏有限公司 2020-07-24 CN claimed
EP-3237903-B1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RES & ENG CO (US) 2020-02-26 EP claimed
EP-3212645-B1 PROCESS FOR MAKING TRICYCLIC LACTAM COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-11-28 EP claimed
US-9969735-B2 Process for making tricyclic lactam compounds GENENTECH, INC. (US) 2018-05-15 US claimed
US-20170313704-A1 PROCESS FOR MAKING TRICYCLIC LACTAM COMPOUNDS GENENTECH, INC. (US) 2017-11-02 US claimed
EP-3237903-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP claimed
EP-3237904-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP claimed
EP-3212645-A1 PROCESS FOR MAKING TRICYCLIC LACTAM COMPOUNDS F. Hoffmann-La Roche AG (CH) 2017-09-06 EP claimed
WO-2016106211-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO claimed
US-20160187315-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US claimed
WO-2016106214-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO claimed
US-20160187314-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US claimed
WO-2016066490-A1 PROCESS FOR MAKING TRICYCLIC LACTAM COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2016-05-06 WO claimed
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 US disclosed
EP-4055016-B1 GPR52 MODULATOR COMPOUNDS NXERA PHARMA UK LTD (GB) 2026-04-29 EP disclosed
US-20260103474-A1 NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES AC IMMUNE SA (CH) 2026-04-16 US disclosed
US-20050043346-A1 Pyridylpyrrole derivatives active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-02-24 US disclosed
US-20050043323-A1 Pyrimidylpyrrole derivatives active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-02-24 US disclosed
WO-2005013986-A1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2005-02-17 WO disclosed
WO-2005014572-A1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043346-A1 Pyridylpyrrole derivatives active as kinase inhibitors MAP3K6, MAP3K5, MAP4K2 USP2 3374/4885SMN1; SMN2 2469/4885DDB1 1516/4885
US-20170313704-A1 PROCESS FOR MAKING TRICYCLIC LACTAM COMPOUNDS COASY, MRPL21, SBDS USP2 1465/4885SMN1; SMN2 3036/4885DDB1 2404/4885
US-20050043323-A1 Pyrimidylpyrrole derivatives active as kinase inhibitors TYMP, DTYMK, DCK USP2 3550/4885SMN1; SMN2 2627/4885DDB1 939/4885
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS USP2 1960/4885SMN1; SMN2 2043/4885DDB1 487/4885
US-20260103474-A1 NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES TARDBP, FUS, HNRNPH3 USP2 1769/4885SMN1; SMN2 32/4885DDB1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.